ArticleAnnals of surgical oncology2026
Impact of Age on Use of Neoadjuvant Chemoimmunotherapy and Outcomes for Patients with Triple-Negative Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Do Older Triple-Negative Breast Cancer Patients Respond Differently to Neoadjuvant Chemoimmunotherapy?Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFollowing KEYNOTE-522, there is limited population-level data regarding the use and outcomes of neoadjuvant chemoimmunotherapy (NACI) for triple-negative breast cancer (TNBC) management across patient ages. We examined trends in the use of NACI and neoadjuvant chemotherapy (NAC) without immunotherapy in TNBC patients stratified by age groups and impact on pathological complete response (pCR) and overall survival (OS).
methodsAdult women with nonmetastatic TNBC who underwent NAC/NACI between 2012 and 2022 were selected from the National Cancer Database. These patients were compared overall and stratified by age group (< 50 years, 50-70 years, and >70 years) based on receipt of NACI or NAC.
resultsA total of 56,606 patients were included. Use of NACI significantly increased from 2012 to 2022 with a concomitant decrease in NAC (p < 0.0001), although women >70 years received significantly less NACI in 2022 than other age groups (p < 0.0001). Women had greater pCR rates in the breast and axillary lymph nodes with NACI compared with NAC overall (relative risk 1.405, p < 0.0001), with women >70 years receiving the greatest benefit (relative risk 1.56, p < 0.0001). All women had greater OS with NACI over NAC (hazard ratio 0.704, p < 0.0001), especially women 50-70 years.
conclusionsUse of NACI for TNBC patients has increased over the past decade. NACI was associated with higher pCR rates and greater OS over NAC in all women, especially > 70 years. These data suggest that older TNBC patients may achieve significant clinical benefit from this regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.